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Teaser This review provides an overview of nonclinical in vivo models that can be used to
support orphan designation in selected rare infectious diseases in Europe, with the aim to
inform and stimulate the planning of nonclinical development in this area of often
neglected diseases.
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Introduction
The European Orphan Legislation came into force in 2000, introducing a system of incentives for
the development of medicines in rare diseases in the EU. COMP of the EMA is responsible for the
scientific assessment of OMPD (see Glossary) applications. COMP evaluates the following criteria
that are laid down in the EU Orphan Regulation: the rarity of the condition; the chronically
debilitating or life-threatening aspects of the condition; the medical plausibility of the
product in the condition; and the assumption of significant benefit over existing treatment
methods [1]. At the time of initial OMPD, applicants are responsible for providing nonclinical
and/or preliminary clinical evidence in support of medical plausibility. Nonclinical data are
commonly used for proof of concept when considering the rarity of the orphan conditions and
the possibility of submitting for OMPD at any stage of development. Thus, the quality of the
submitted nonclinical evidence becomes crucial for obtaining OMPD, which ultimately unlocks
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ing authorization. Challenges regarding other criteria of OMPD
have been discussed elsewhere [2–4].
The Orphan Regulation resulted in a significant boost to the
development of medicines for rare diseases [1]. By the end of
2018, 2134 medicines had been granted orphan status by the
European Commission (EC) for a total of 524 distinct rare con-
ditions [5]. Approximately 30% of these designations were
granted at an early stage of product development, when only
nonclinical proof-of-concept data were available [6]. Despite the
rarity of the conditions and objective challenges of product
development in such context, 164 orphan products (of which
only 115 currently retain orphan status) have been authorized
since the regulation came into force, with the estimated accrual
rate of products in development no higher than that expected for
a nonorphan product (1/10) [5,7,8].
In this review, we focus on infectious diseases, a therapeutic area
that has been underrepresented in COMP analyses to date but is
viewed as being particularly important. In Europe, rare infectious
diseases with limited treatment options still pose a relevant threat
and belong to either of two groups: diseases considered eradicated,
but gravely dangerous in case of an outbreak; or diseases neglected
in their endemic epidemiological regions, which occasionally
occur also in Europe. Orphan regulation in this context presents
an incentive to develop medicines potentially needed in the event
of, for example, a terrorist attack leading to an outbreak of an
eradicated disease, such as smallpox, or an incentive to develop
medicines for a globally common disease, for which treatment
options are limited, as is the case of tuberculosis (TB). Providing
robust proof-of-concept data in a nonclinical setting can be chal-
lenging in some of these conditions.
The predictive value of all nonclinical models is limited, and
one cannot underestimate the importance of clinical data in the
development of a medicine. In addition, enhanced nonclinical in
vitro techniques are currently being developed and some are
already recognized by regulators as satisfactory substitutes for in
vivo models in the nonclinical part of an application for marketing
authorization. However, this review should be seen from the
perspective of the regulatory committee, COMP, responsible forTABLE 1
Disease-relevant endpoints accepted by COMPa
Pathogen Condition Dise
Avian influenza A Virus Avian influenza Surv
Ebola virus EVD Surv
VARV Smallpox Surv
Cowpox virus Smallpox, cowpox Peak
Monkeypox virus Smallpox, monkeypox Peak
VV Vaccinia, smallpox Surv
virus
Bacillus anthracis Anthrax infection Surv
Mycobacterium tuberculosis TB (severe, refractory)a Surv
Fungi of the Mucoraceae Mucormycosis Surv
Acanthamoeba Acanthamoeba (keratitis)a Amo
Leishmania (donovani and others) (Visceral)a leishmaniasis Redu
imm
Plasmodium (falciparum and others) (Severe)a malaria Paras
effec
a Aspect of the disease addressed in application, not highlighted in the wording of the orphmaking an informed decision about the potential of a medicine at
an early stage of development, when in vitro data might still be
difficult to accept in the absence of preliminary clinical efficacy
data. That said, COMP considers ethical and scientific arguments
when assessing the nonclinical models used [9]. In this review, the
COMP Non-Clinical Working Group provides guidance on the
acceptability of animal models in selected infections for which
designations were granted, and further comments on the short-
comings of unsuccessful applications, which can be easily avoided
if the nonclinical development plan is well planned and focused
on answering regulatory relevant questions.
In this review, we focus on infectious diseases considered rare
within the EU, based on data from OMPD assessed by the COMP
between 2000 and 2017. Non-rare infections that occur in rare
diseases (e.g., infections in cystic fibrosis) were not considered,
because the clinical aspects addressed in such applications were
considered pertinent to the underlying rare disease. It is an analy-
sis that is methodologically similar to a previous COMP Non-
Clinical Working Group review of the nonclinical data in applica-
tions for OMPD in neurological diseases [10]. We provide a table of
nonclinical disease-relevant endpoints (Table 1) for the pur-
pose of OMPD. Our aim is to comment on the evidence that can be
used to support future OMPDs and the proof-of-concept studies in
infectious rare diseases.
Avian influenza
Avian influenza A viruses, other than H1 or H3, represent a major
threat of pandemic disease, because humans lack immunity to
most influenza A subtypes. Avian influenza A viruses have been
divided in ‘Highly’ and ‘Low’ Pathogenic Avian Influenza viruses
(HPAI and LPAI, respectively), based on their molecular character-
istics and ability to cause disease and mortality in chickens in a
laboratory setting. The first HPAI that infected humans in 1997
was H5N1 during a poultry outbreak in Hong Kong. Since its
widespread re-emergence from 2003 to 2006, this avian virus
has spread from Asia to Europe and Africa, resulting in millions
of poultry infections, and several hundred cases in humans, with
many human deaths. H5N1 influenza is caused by a specific viral
strain subtype and, therefore, is considered to be a distinct condi-ase-relevant endpoint
ival in mice; in vitro neutralization activity of equine anti-H5N1 antibodies
ival, resolution of fever and clinical symptoms, reduction of viremia
ival, respiratory rate, weight loss, development of secondary lesions
 viral load, mortality
 viral load, mortality
ival/weight (after a lethal viral dose); dermal lesion formation/progression;
-specific antibody titers; cytokine levels and viremia
ival
ival, lung/spleen colony-forming unit
ival
ebic growth inhibition, infection severity grading (opacity of infected corneas)
ction of parasite load in liver and spleen, bone marrow, parasite clearance,
une response, physical examination in dogs
itemia clearance, mortality, likelihood of recrudescence, percentage of cure,
tive dose assessment
an condition.
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aggressive clinical course with rapid deterioration and high fatality
rate. H5N1 influenza in humans is poorly characterized in terms of
clinical endpoints. Typical systemic and respiratory symptoms
include fever, chills, aches and pain, cough, and sore throat.
However, avian influenza can also lead to life-threatening pneu-
monia and secondary bacterial infections. The incubation period
ranges from 2 to 8 days and possibly up to 17 days, which is longer
than for common influenza. Other avian influenza A virus sub-
types are also of concern, such as the H7N7 [11] and the H7N9
viruses [12].
Five main animal species [nonhuman primates (NHPs), mice,
ferrets, pigs, and cats] have been proposed and used as models of
H5N1 influenza infection OMPD applications (Table 2). From a
pathophysiological point of view, the best model in literature is
the NHP, although its use is largely limited because of ethical
concerns, the complexity of husbandry practices, and the difficul-
ties in achieving statistical significance with the use of a reduced
number of animals [13]. From a practical point of view, and
considering the pros and cons, the mouse model is more appro-
priate and acceptable. The inflammatory effects on the respiratory
apparatus are similar to those in humans. Ferrets are also consid-
ered a valid model because their pathophysiological and symp-
tomatic characteristics are similar to those in humans. These
models have all proven to be suitable to evaluate the efficacy of
vaccines and antiviral drugs [14]. By contrast, guinea pig and cat
animal models now are less used in drug discovery, also because of
their low predictive value [14]. In some cases, rodent models
(BALB/c mice) with survival as the main endpoint are still usedTABLE 2
Models of avian influenza infectiona
Animal model Method of generation Features of the model 
NHP:
Cynomolgus
macaque
Infection with multiple H5N1
strains inoculated through
different routes
Respiratory tract is major t
acute respiratory distress
syndrome, fever, nasal
discharge, sneezing, letha
weight loss
Mouse: BALB/c
and C57bl/6
Infection with multiple H5N1
strains inoculated through
different routes
Pulmonary infection, with
systemic spread; weight lo
huddling, ruffled fur, letha
hypothermia; high lethalit
Ferret Infection with multiple H5N1
strains inoculated through
intranasal route
Virus replication in upper 
lower respiratory tract and
multiple organs including 
Severe lethargy, fever, wei
loss, transient lymphopen
Guinea pig Infection with multiple H5N1
strains inoculated through
intranasal route
Virus replicates in respirat
tract but not in other tissu
Tracheobronchitis,
bronchointerstitial pneum
nasal discharge, cough, la
breathing, fever, weight lo
Cat Infection with H5N1 strains
inoculated through
intratracheal route or feeding on
virus-infected chicks
Virus detected in respirato
digestive tract, nervous,
cardiovascular, urinary,
lymphoid, and endocrine t
fever, conjunctivitis, lethar
labored breathing
a Take-home message: mouse model is acceptable to support the orphan designation becau
significance.
276 www.drugdiscoverytoday.comfor proof-of-concept purposes and these have been accepted so far
by COMP (Table 1).
Ebola
Ebola Virus Disease (EVD) is caused by infection with a virus of the
family Filoviridae, genus Ebolavirus, a family of enveloped, non-
segmented negative-sense (NNS) RNA viruses. Outbreaks of Ebola
happen sporadically in Africa. The 2014–2016 West Africa out-
break was from a new strain of the Zaire species (EBOV) with a
reported case-fatality rate of 55%. Given this high mortality, Ebola
viruses are considered Category A Bioterrorism Agents by the US
Center for Disease Control (CDC) and as priority pathogens need-
ing urgent research by the WHO. Accordingly, research with Ebola
viruses is performed under Biosafety Level 4 (BSL4) conditions. The
natural reservoir host of Ebola viruses has not yet been identified,
but it is likely that the first patient becomes infected through
contact with an infected animal, such as a fruit bat or primate. The
virus can then be spread between humans through direct contact
with body fluids (including blood and semen) and contaminated
objects.
EVD is associated with rapid virus replication pervading most
tissues and accompanied by widespread and severe focal necrosis
[15]. The virus is generally detectable by PCR 48 h after infection in
both lethal and nonlethal cases. However, symptoms usually occur
after an incubation period of 4–10 days (or less commonly between
2–21 days). After a sudden onset of ‘flu-like’ symptoms (fever,
myalgia, and chills), and vomiting and diarrhea, the disease can
rapidly evolve into a severe state with a rapid clinical decline and
death due to shock, hemorrhage, and multiorgan failure.Advantages of model Disadvantages of model Refs
arget;
rgy,
Similar symptomatology
to human
Different pathophysiology;
ethical concerns
[85,86]
ss,
rgy,
y
Similar pathogenesis to
human; easier for
statistical analysis and
husbandry
Different clinical symptoms and
signs than in humans
[87,88]
and
 in
brain.
ght
ia
Similar pathophysiology
and symptoms to human
Inoculation routes other than
intranasal pose difficulties.
Paucity of laboratory reagents
[89,90]
ory
es.
onia,
bored
ss
Similar pathophysiology
to human
Paucity of laboratory reagents;
lacks many of clinical signs seen
in humans
[91,92]
ry,
issue;
gy,
Pattern of H5N1 virus
attachment to lower
respiratory tract cells
closely mimics that
observed in humans
Ethical concerns, complex
husbandry and low availability
[93]
se of the similar pathogenic mechanisms, accessibility, and easy-to-reach statistical
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NHPs, especially cynomolgus or rhesus macaques (favored NHP
models). As already mentioned, NHP studies are expensive and
limited for ethical reasons, and they are usually performed at late
nonclinical stage, once proof of concept has been obtained in
smaller models. The nonclinical endpoints accepted so far by
COMP are similar to the known clinical endpoints. This is because
of the similarities of the clinical features of EVD in humans to
those observed in nonclinical models (Table 3).
Five products have obtained OMPD for the treatment of EVD and
all designations to date have been based on nonclinical data. When-
ever studies in NHP models were not available, mouse models were
considered acceptable when methodology and results were robust.
Among small animals, mouse models show rapid onset of viremia
and high viral burden in the spleen, liver, and multiple organ tissues.
Lymphopenia, thrombocytopenia, kidney dysfunction, and liver
damage are also observed. However immunocompetent mice are
resistant to wild-type EBOV (WT EBOV); thus, mouse-adapted EBOV
is needed for the infection to occur. By contrast, WT EBOV is lethal to
suckling mice and immunodeficient mice (e.g., SCID mice), which
lack functional B and T cell responses. Therefore, it is possible to
challengemicewitha mouse-adaptedMayingaEBOV strain. InsomeTABLE 3
Models of Ebola virus infection and/or diseasea
Animal model Method of generation Features of model 
NHPs
(Cynomolgus
macaque is
preferred)
Experimental infection Fever, anorexia, rash, increase i
liver enzymes and disruption o
coagulation
Mouse:
collaborative
cross mouse
Infections in cross of
eight inbred founder
mouse strains (C57BL/6
J, A/J, 129S1/SvImJ,
NOD/ ShiLtJ, NZO/H1LtJ)
and three wild-derived
strains
Rapid onset of viremia and hig
viral burden in spleen, liver, an
other organs; lymphopenia,
thrombocytopenia, kidney
dysfunction, liver damage
Mouse:
humanized
mouse model
NOD/ShiLtJ
background
Infections in NOD/ShiLtJ
strain
Defects in antigen presentation
T lymphocyte repertoire, natura
killer cell function, macrophag
cytokine production, wound
healing, C5 complement
Syrian hamster Experimental infection Fever, anorexia, and
dehydration; drop in platelet
count, increased fibrin
deposition and prolonged
prothrombin and partial
thromboplastin time
Duncan–Hartley
and Strain 13
guinea pigs
Experimental infection Virus detected in lymph node
macrophages 24 h after
inoculation, spreads to spleen
and liver thereafter, and
subsequently to other organs
and tissues
a Take-home message: generally, the model of choice to study medical plausibility in Ebola wou
COMP would also accept data generated in small model organisms, such as mice.cases, studies in NHP models were also available and used to support
medical plausibility.
Orthopoxvirus infections
Currently, ten species of virus are included in the genus Ortho-
poxvirus, which belongs to the Poxviridae family. For regulatory
purposes, each individual pathogen is considered to cause a sepa-
rate orphan condition (e.g., smallpox infection, monkeypox in-
fection, etc.) and, thus, individual applications for each virus are
generally required.
Smallpox and vaccinia are caused by Variola virus (VARV) and
Vaccinia virus (VV), respectively. Smallpox was declared eradicated
in 1980 because of successful prophylactic vaccination during the
20th century [16]. Replication of VARV occurs in the cytoplasm
and infected macrophages carry the virus to the lymph nodes.
Consequently, small vessels of the dermis become infected, result-
ing in the typical skin pustules [17]. Clinical forms of smallpox can
be divided into five varieties: ordinary, modified, variola sine
eruptione, flat, and hemorrhagic. Cytopathic effects of the virus
can lead to death, although the cause of death remains controver-
sial, because multiple mechanisms are involved. Mortality of
smallpox was~30%, killing~500 million people over the past 100Advantages of model Disadvantages of model Refs
n
f
EBOV infection in NHP
recapitulates human disease
in clinical symptoms, and
histopathology;
Cynomolgus macaques can
be used for vaccine studies
and Rhesus macaques for
postexposure studies
Ethical concerns, complex
husbandry requirements
and low availability; limited
space in BSL4 facilities
[94–97]
h
d
Useful for screening for new
compounds
Model presents with only a
few features of human
disease; no consensus on
validity of any existing Ebola
infection mouse models,
which makes it difficult to
interpret data;
immunocompetent mice are
resistant to WT EBOV. In mice
infected with mouse-
adapted EBOV, no
coagulopathy is observed
[98]
,
l
e
Common choice for Ebola in
immunodeficiency
[99]
Infection with mouse-
adapted-EBOV is similar to
that in humans, including,
severity of coagulopathy,
which does not occur in
mouse and guinea pig.
Pathology of spleen and liver
similar to human
Limited availability of
hamster-specific laboratory
reagents
[100]
Allows larger sampling sizes;
histopathology similar to
mice, NHPs and human; can
be used for antibody therapy
testing
Strain 13 shows altered
immune response, not fully
representative of human
Ebola
[100]
ld be NHP despite all the ethical considerations. However, for an orphan designation, the
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global health emergency [18].
No animal reservoirs exist in nature, and most animal species
cannot be infected even in the laboratory [19]. Smallpox is also
challenging to study because of biosafety restrictions. Therefore,
surrogate disease models are needed. In this context, to facili-
tate drug development when circumstances do not allow proper
clinical evaluation, the US Food and Drug Administration (FDA)
issued the ‘Animal Rule’, which states that efficacy data can be
obtained from appropriate animal models and bridged to humans
[20]. Indeed, the research of smallpox treatment is ongoing as
evidenced by a recent (2018) FDA first approval of a drug for this
pathogen, tecovirimat [18]. Interestingly, in Europe, tecovirimat
has been granted an OMPD for the treatment of cowpox, but so far
no further regulatory steps have been taken towards marketing
authorization in Europe.
One application exploring the efficacy of the drug in rabbits
infected with a surrogate Orthopoxvirus, rabbitpox, was presented
to COMP [21]. The advantage of the rabbitpox model is the ability
to produce a natural aerosol transmission of the virus between
animals with secondary lesions, although the rabbitpox infection
does not occur in humans. Other models comprising Orthopoxvirus
in the literature include VV, ectromelia, cowpox, and monkeypox
virus in mice [22]. Interestingly, besides VV, monkeypox and
cowpox [23] also infect humans. Although mice models can be
used in studies that are practical and can reach statistical power,
the differences in immune system responses between mice and
humans can result in differences in epitope recognition, thus
hampering translatability to humans [22]. Notably, the Ind-3a
strain of VARV was explored by the Institute of Cancer Research
(ICR) in SCID mice [24].
Monkeypox virus was additionally used to infect monkeys [25],
squirrels [26], prairie dogs [27], and pigs. Moreover, this virus was
administered via the intranasal inoculation route to mimic natural
infection in hamsters, rabbits [28], rats [29,30], and mice [28,31–
35]. However, because the human infectious monkeypox dose is
unknown, it is hard to establish the translational benefit of these
models [36].
The cowpox virus, another member of Poxviridae, shares homol-
ogy with monkeypox and VARV [37], which allows the use of this
virus as a model to study smallpox [38]. Importantly, in contrast to
VARV, both cowpox and monkeypox virus require a lesser bio-
safety 2 level to work with.
The authentic VARV is able to infect cynomolgus monkeys,
specifically the Harper and India 7124 strains. The model is
characterized by systemic disease with features of human smallpox
with a high lethality [39].
Overall, the ideal model would have the characteristics of a
generalized dissemination with secondary lesions, in animal-to-
animal spread, and high lethality. Given that no animal model
perfectly mimics smallpox in humans, it is considered more
suitable to test the efficacy in several animal models to increase
the translatability to human smallpox. However, with regard to
the OMPD, data produced in one animal model would be accept-
able.
VV infects not only the reservoir species (most likely candidates
are sylvatic rodents), but also humans, resulting in a skin infection.
In a generalized infection, virus spread is thought to occur through278 www.drugdiscoverytoday.comthe regional lymphatics to the bloodstream, resulting in primary
viremia [40]. Clinical signs of generalized vaccinia include a diffuse
erythematous maculopapular rash scattered over the body;
papules become vesicles and generally heal over within 15 days,
leaving a typical scar in the skin of people and animals affected
[41]. Clinical characteristics of vaccinia complications, especially
in immunocompromised patients, include eczema vaccinatum in
patients with a history of eczema or atopic dermatitis, persistent
infection with tissue necrosis (vaccinia necrosum), postvaccinal
encephalitis, myocarditis, and ischemic cardiac events [42–44].
Vaccinia vaccination is necessary after a smallpox outbreak or after
a bioterrorist attack (Table 4).
For VV infection, there are several available rodent models in
which disease-relevant endpoints can be measured (Table 4). These
models mimic certain aspects of the disease (e.g., progressive
cutaneous infection in an immunocompromised host) and can
be considered valuable to study how VV modulates the host
immune response. However, unlike the intranasal route of infec-
tion, intradermal inoculation is localized, without generalized
clinical signs of illness similar to those observed during intranasal
infections (e.g., weight loss) [45]. For the purposes of OMPD,
presentation of data in one valid animal model would be suffi-
cient.
Anthrax
Bacillus anthracis (B. anthracis) is a Gram-positive, rod-shaped
bacterium. Human infection can be naturally acquired from con-
tact with infected grazing animals that have ingested soil contam-
inated with B. anthracis spores, or from occupational exposure to
infected and/or contaminated animal products. This type of in-
fection is usually cutaneous or, less frequently, gastrointestinal.
The inhaled forms of the infection are usually accidental or
related to bioterrorism, although they often occurred previously in
industrial settings, such as while working with wool. B. anthracis
spores germinate within the alveolar lung macrophages and pro-
duce anthrax toxin, responsible for triggering the cascade of
inflammatory events and starting the clinical manifestations of
the disease. The incubation period of inhaled anthrax typically
lasts 2–10 days, and the first symptoms are flu-like, followed by a
rapidly progressive phase of systemic manifestations culminating
over the course of 12–24 h in the development of bacteremia and
rapid clinical deterioration with high fever, dyspnea, and shock,
with 100% death rates. Cutaneous forms are the mildest, often self-
limited, with mortality of ~20% if untreated. The available treat-
ments for anthrax infection comprise antibiotics. Still, survival is
poor at 50–60% in nonclinical models, which provide the only
indicative data of disease-relevant activity because the clinical
experience in inhalation anthrax is limited. All the OMPDs
granted so far target the inhalation form of anthrax infection.
Selecting animal model for studies on anthrax might be com-
plex, because it dependents on many interrelated factors, such as
the specific aim of the research, the differing attributes of the
animal species, and the manner and route of exposure. The best
animal models developed for the evaluation of anthrax counter-
measures are NHP and rabbit models. However, limitations, such
as costs, ethical issues, housing and maintenance constraints,
restrict their use for the final evaluation of medicinal products,
just before licensure for human use [46]. During the initial steps of
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TABLE 4
Models of Orthopoxvirus infectiona
Animal model Method of
generation
Features of the model Advantages of model Disadvantages of model Refs
Models of VARV infections
Rabbit: New Zealand
white rabbits –
rabbitpox; Vaccinia
(WR strain)
Intradermal infection
through thighs.
Disseminated lethal disease at very low
inoculum with secondary lesions,
respiratory involvement, and natural
aerosol transmission between animals
Genetic similarity to VARV, similar
pathophysiology to human disease, low
dose of virus leads to lethal disease,
correlation of viral burden with disease
progression, model of disease with
lesions
Short incubation time with short
survival after infection
[18,101]
Mouse: variola Intranasal challenge
with strain Ind-3a of
VARV in
immunocompetent
ICR mice and
immunodeficient
SCID mice
Infection restricted to respiratory
organs, not progressing to second and
third stages
Prophylactic research, high
susceptibility to virus; great similarity
regarding inflammatory destructive
effect on respiratory tract organs
Asymptomatic infection; infection
limited to brain and respiratory tract;
not suitable for study of therapeutic
treatments
[22]
Mouse: vaccinia
BALB/c, C56BL/6
Intraperitoneal,
intranasal infection
Challenge with virus induces cellular
and humoral immune responses
Statistical power, practicality of model Lack of obvious vascular involvement;
lethal infection requires a substantial
viral inoculum; pathology of advanced
disease differs from smallpox in human
[22]
Mouse: ectromelia
(mousepox)
Intranasal infection,
application through
scars on tail
Infections at low virus doses,
transmittable between mice; disease
severity dependent on mouse, virus
strain, and route of infection
Statistical power, practicality of the
model; natural pathogen of mice
Rapid mortality precludes development
of lesions
[22]
Mouse: cowpox Intradermal,
intratracheal
Disease course analogous to smallpox
in humans
Virus highly virulent for mice; human is
a natural host
Large viral inoculum needed to obtain
lethal infection; pathology of advanced
disease differs from smallpox in human
[22]
Mouse: monkeypox Intranasal,
intratracheal,
intraperitoneal
Systemic disease: virus detected in
multiple organs, including lungs and
kidneys; pustule lesions
Human is a natural host Absence of rash [32,36]
Rat: vaccinia Intradermal,
intravenous
Bioluminescent imaging in live
organism
Statistical power, practicality of model Absence of primary lesions [102]
Monkey: monkeypox Intravenous,
intratracheal
Necrotizing lesions at all affected sites,
including lungs, lymph nodes, thymus,
spleen, skin, oral mucosa,
gastrointestinal tract, and reproductive
system
More severe disease in NHPs; good
surrogate for human smallpox
Limitations in group size and ethical
considerations
[22]
Monkey: variola Intravenous, aerosol Uniform acute lethality when
inoculated intravenously in high doses;
lower doses result in less fulminant,
systemic disease and lower mortality
Mimics incubation and prodromal
phases of human smallpox by creating
instantaneous viremia and systemic
spread of virus to target tissues
Less susceptible to virus than humans;
ethical concerns, complex husbandry,
limited availability
[22]
African dormouse:
monkeypox
Intranasal Replication in nasal mucosa causing
necrosis and hemorrhage with systemic
spread to lymph nodes, spleen, liver,
and other tissues, causing severe
necrosis and/or hemorrhage leading to
death
Many of histopathological features
similar to those in smallpox-infected
humans
Not specifically noted in consulted
literature
[36]
Squirrel: monkeypox Intranasal, oral,
scarification routes
Airborne and direct contact
transmission to healthy animals
High susceptibility to virus challenge No skin lesions [36]
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TABLE 4 (Continued )
Animal model Method of
generation
Features of the model Advantages of model Disadvantages of model Refs
Prairie dog:
monkeypox
Intranasal,
intraperitoneal,
scarification route
Congo Basin and West African clade
used; necrotizing bronchopneumonia,
conjunctivitis, and tongue ulceration
High susceptibility to virus challenge Not specifically noted in consulted
literature
[36]
Models of VV infection
Mouse: C57BL/6 Intradermal
inoculation in left ear
dorsal pinna
Viral pathogenicity assessed based on
lesion formation and size
Resembles scarification route used
during smallpox vaccination; valuable
model to study how VV modulates host
immune response
Localized infection, no generalized
clinical signs of illness like those
observed during intranasal infections
[45]
Intranasal inoculation Model of protective vaccination based
on infected mice maintaining weight
Disease-relevant endpoint (weight
maintenance)
No skin lesions
Mouse: BALB/c Intraperitoneal Mice develop virus-specific neutralizing
antibodies, immune responses can be
measured
Can be used in other Orthopoxvirus
diseases; good for studying mechanism
of poxvirus-induced innate and
adaptive immune response
No skin lesions [103]
Orally ingested
contaminated VV
milk
Generalized infection; virus-specific
neutralizing antibody titers and viral
DNA titers in fecal, blood, and tissue
samples
Pathogenesis and distribution of virus
through all organs; virus-specific
neutralizing antibody titers as disease-
relevant endpoint
No skin lesions
Intranasal Reduced survival; acquired protective
immunity can be tested with a
secondary lethal dose of virus and
assessed measuring weight, virus-
specific antibody titers and cytokine
production in lungs and spleen
Good for studying acquired protective
immunity; virus-specific neutralizing
antibody titers as disease-relevant
endpoint
No skin lesions
Mouse: Nc/Nga Intranasal inoculation Atopic mouse model sensitized with
ovalbumin to induce spontaneous skin
lesions and elevated serum levels of
immunoglobulin (Ig)E; mice develop
atopic dermatitis
Similar to human atopic dermatitis;
pathology of eczema vaccinatum can
be studied
No skin lesions [104]
Rabbit: New Zealand Intranasal inoculation
of Bovine
Herpesvirus 1
Glycoprotein D
(BoHV-1)
Mice develop virus-specific neutralizing
antibodies, immune responses can be
measured
Mechanism of poxvirus-induced
immune response can be studied; well-
established model to study
pathogenesis and natural route of
BoHV-1 infection, and efficacy of cattle
vaccines
No skin lesions [105]
Rat: Rag2–/– Intradermal
inoculation in
immune-deficient
females
Viral load/clearance rate in tissues in
published study was monitored using
luciferase bioluminescence assays
Suitable visualization model that
recapitulates infectious and clinical
features of human smallpox in
immunodeficient populations
Not specifically noted in consulted
literature
[102]
Mouse Ifngr1tm1
knockout
Mice homozygous for
Ifngr1tm1 knockout
mutation
Mice have normal T cell responses but
are defective in natural resistance
Increased susceptibility to VV infection Not specifically noted in consulted
literature
[99]
Mouse Mb21d1
(cGAS) knockout
mice
Mice homozygous for
Mb21d1 knockout
mutation
Homozygotes challenged with VV
exhibit higher viral titers and mortality
Increased susceptibility to DNA viruses
(VV andWest Nile virus infection); useful
in studies of response to viral infection
or cytosolic DNA
Not specifically noted in consulted
literature
[99]
a Take-homemessage: variousOrthopoxvirusmodels can and are being used interchangeably to explore treatment efficacies in smallpox, vaccinia, monkeypox, and cowpox. Mousemodels for VV infectionmimic clinically relevant endpoints of
vaccinia and were considered valuable by COMP to support orphan designation because of their predictive value, based on a similar pathophysiology. Adequate data produced in one animal model are sufficient for orphan drug designation
purposes.
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TABLE 5
Models of anthraxa
Animal model Method of
generation
Features of the model Advantages of model Disadvantages of model Refs
NHPs: Rhesus
macaque,
Cynomolgus
macaque, African
green monkey
Aerosolized B.
anthracis, intranasal,
intubation, trans-
tracheal
Onset of disease 3–25 days post
challenge; can die acutely with
no clinical sign of disease;
edema, hemorrhage, and
necrosis in lungs; damage to
mediastinum, meninges,
adrenal glands, gastrointestinal
tract, and urogenital organs
Fully mimics human
infection; develops anthrax
meningitis; similar PK/PD
parameters as in human; can
be used to estimate human
administrations and
dosages; good as a vaccine
model
Ethical considerations,
supply limitations, complex
maintenance
[106–112]
Rabbit: New Zealand
White rabbit, Dutch
belted rabbit
Challenge with fully
virulent strains of B.
anthracis,
subcutaneous
injection, intranasal,
or aerosol exposure;
most often aerosol in
a muzzle-only mask
Susceptible to lethal infection;
clinically less severe than in
NHPs and humans; no
occurrence of meningitis.
Pathology similar to humans
regardless of infection route;
clinical similarities with
human anthrax, especially
cardiac involvement;
accepted vaccine and
therapeutic drug model
Lack of a clear dose
response; different to human
anthrax (i.e., significant CNS
involvement), more acute
disease in rabbits; innate
sensitivity to some
antibiotics, limits use in
therapy studies
[113]
Guinea pig B. anthracis/spore
challenge: resistant
to toxin
Different symptoms from
human (no fever)
Good for studying
pathogenesis of inhalational
anthrax; allows collection of
adequate amounts of tissues
for analyses, and small
enough to allow adequate
cohort sizes
Performs poorly with ‘cell-
free’ or subunit vaccines
because of limited efficacy;
unique pathogenesis
different from human
[110,114–116]
Mouse: various
strains;
immunocompetent
C5 mice (e.g., C57Bl/
5)
Virulent toxin
challenge
Time to death after challenge:
3.3 days; acute disease
characterized by extensive
edema and large titer of bacilli in
blood and organs
BALB/c survive longer,
enabling medicine testing.
A/J mice die quickly after 2
days; attenuated B. anthracis
can be studied under
biosafety level 2 conditions
Not adequate to test
aluminium adjuvanted;
protective antigen vaccines;
pathology does not
represent human condition
[114,117–120]
Mouse:
immunodeficient
(C5)
Attenuated strains of
B. anthracis challenge
Death after low doses Useful for studying role of
toxins in pathogenesis and
for preliminary efficacy of
vaccines and therapeutics
Not specifically noted in
consulted literature
[110]
Rat Toxin challenge Relatively resistant to parenteral
challenge with spores, but
extremely sensitive to injected
anthrax toxin
Sensitive model for efficacy
of antitoxin medicines
Not an ideal model for whole
B. anthrax/spore challenge
[118,121]
a Take-home message: COMP would find the rabbit model most appropriate to study medical plausibility, and the addition of NHP data could support authorization of the product based
on nonclinical data only.
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rats, have been used to study the pathogenesis, treatment, and
prevention of anthrax (Table 5).
The products that received OMPD include several monoclonal
antibodies directed against the anthrax toxin, which have shown
significant improvement of survival in nonclinical models, alone
and when administered in combination with antibiotics. The
designated products were tested in rabbits and/or NHP (Table
5). Both NHPs and rabbits have been accepted by the COMP as
models for the development of new medicines and vaccines for
anthrax. These models were also accepted by FDA as valid models
in the authorization of anthrax products under the animal rule
[46]. For treatment purposes, the candidate products are usually
administered upon detection of significant increase in body tem-
perature and/or anthrax protective antigen (PA) in the serum,
which is considered by the COMP as a valid approach.
Tuberculosis
Mycobacterium tuberculosis infects mainly lungs, but can spread to
other organs, producing extrapulmonary TB. Infection occurs uponinhalation, when the infectious droplets settle in the airways, pre-
dominantly in the upper part of the respiratory tract. The immune
system responds through macrophages that present mycobacterial
antigens to T cells. Macrophages then envelop the bacteria, forming
granulomas, where it continues to reproduce, eventually killing the
immune cell and producing solid necrosis [47].
Applications for products intended for TB treatment have been
presented several times to COMP. From the ten applications
submitted, only one represented a vaccine, whereas the rest were
intended for already infected individuals. All applications pre-
sented data with a nonclinical mouse model of the infection,
while one was complemented with additional guinea pig model
data. Additionally, TB models utilizing the New Zealand rabbit,
Cynomolgus macaque, Chinese tree shrew, Wistar rat, castrated
male Friesian-cross calf, and zebrafish larvae or adult zebrafish are
known (Table 6) [48].
The mouse TB model is characterized by homogeneous patho-
logical changes and bacterial burden, which makes it an appropri-
ate model for rapid anti-TB chemical drug evaluation. However,
mice have a varied length of latent period, with high bacterialwww.drugdiscoverytoday.com 281
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TABLE 6
Models of TBa
Animal model Method of
generation
Features of the
model
Advantages of model Disadvantages of model Refs
Mouse Aerosol or tail vein
infection
Relatively low
susceptibility to
bacteria
Appropriate model to study
vaccines, drugs, immune
mechanisms, and host genetics
Missing obvious clinical expression
of infection, different TB granuloma
structure compared with human;
without disseminated disease,
interindividual variation in infection
[48,122]
Rat Aerosol route
infection
Lower susceptibility
to bacteria than mice
Ideal model to study biological
characteristics and formation of
pulmonary granuloma
Different TB granuloma structure
compared with human; pulmonary
bacterial load in latent infection is
relatively high
[48]
Guinea Pig Aerosol or
subcutaneous
infection
High susceptibility to
bacteria
Replicates many aspects of TB
infection in humans; ideal to test
vaccine efficacy
Paucity of specific immune
reagents; general clinical features of
TB are missing, no spontaneous
latent infection
[48,122]
Rabbit Aerosol infection
with Mycobacterium
bovis
Very low
susceptibility to
Mycobacterium
tuberculosis; M. bovis
is more often used
M. bovis infection resembles
human pulmonary pathology;
used to test pathogenesis of
disease
Missing obvious clinical expression
of infection, missing specific
immune reagents; M. bovis
pathogenesis is different from that
of M. tuberculosis
[48,122]
NHPs Aerosol infection High susceptibility to
bacteria
Ideal for testing pathogenesis
and vaccine or drug
development
Interindividual variation, paucity of
specific immune reagents
[49,122]
Zebrafish (adult and
embryonic larvae)
Infected with
Mycobacterium
marinum via various
inoculation routes
No susceptibility to
M. tuberculosis, but to
M. marinum. Fish
develop necrotic
granulomas
M. marinum infection with
necrotic granulomas resembles
human infection; used for
pathogenesis research and
screening of therapeutics
For infection with M. marinum,
clinical manifestations and
symptoms of TB are missing,
absence of specific immune
reagents
[48,50]
a Take-home message: from the experience of COMP, it can be concluded that the combined use of mice and guinea pig models should be pursued, because their characteristics
complement each other and produce robust data. The Cynomolgus macaque model would be most appropriate because of its similarity to human, but is not required by the COMP
because of ethical reasons.
Review
s
FO
U
N
D
A
TIO
N
R
EV
IEWburdens and heterogeneous starting time points [48]. The guinea
pig model is susceptible to the infection and presents with similar
symptoms and pathophysiology as humans. Thus, this model is
appropriate for the evaluation of vaccines. By contrast, the guinea
pig seldom presents liquefaction and cavitation of pulmonary
granulomas and does not exhibit a latent form of infection [49].
Recently a zebrafish model, an unusual organism for TB because it
does not have lungs, emerged. This model is valuable for visuali-
zation of early steps of TB pathogenesis [50] and, as such, is ideal
for the initial identification of new antimycobacterial drugs. How-
ever, the zebrafish model, if submitted as sole evidence, would not
be enough to substantiate the proof of concept of the product
because of its limitations in reproducing the clinical aspects of TB.
In cases where this model was used as part of a larger nonclinical
development, it would be assessed as supportive evidence on a
case-by-case basis (Fig. 1).
Mucormycosis
Mucormycosis refers to fungal infections caused by species of the
family Mucoraceae, which are members of the order of Mucorales,
Subphylum Mucoromycotina [51]. The most common species
isolated from patients include Rhizopus, Mucor, and Lichtheimia.
These pathogens are ubiquitous in nature and infection is usually
seen in patients who are immunocompromised. In developed
countries, cases are mostly seen in transplant recipients and
patients with hematological malignancies, whereas, in developing
countries, the infection occurs mostly in patients with diabetes
mellitus [51]. The infection is characterized by angio-invasion282 www.drugdiscoverytoday.comresulting in thrombotic and infarcted lesions in the affected
tissues. Based on its clinical presentation and anatomic site,
mucormycosis is classified into six major clinical forms: rhinocer-
ebral; pulmonary; cutaneous; gastrointestinal; disseminated; and
uncommon rare forms, such as endocarditis, osteomyelitis, peri-
tonitis, and renal infection [52].
Several in vivo models have been discussed in the literature using
a plethora of fungal strains (Table 7). Most common references
include neutropenic rodent models infected via different routes,
as, for example, intravenously to generate a disseminated infec-
tion [53] or intratracheally [54] for the production of a pulmonary
phenotype. In those settings, cyclophosphamide or cytarabine can
be used for inducing neutropenia [53,54]. Study endpoints have
included not only survival, but also residual fungal burden and
other endpoints, such as pulmonary infarct scores [54]. Diabetic
mouse models, where diabetes is induced by streptozocin, have
also been used to study mucormycosis [55]. Intranasal challenge of
diabetic mice with Mucoraceae spores results in specific enhanced
susceptibility similar to humans with diabetes. Nonlethal murine
models of cutaneous mucormycosis [56], as well as nonrodent
models [57] have also been discussed.
So far, COMP has granted one successful designation for the
treatment of mucormycosis. The application included, among
others, nonclinical data in a neutropenic mouse model challenged
intratracheally with a strain of Rhizopus oryzae. Neutropenia was
induced by cyclophosphamide and cortisone, and mice were
infected intratracheally and then treated with the study drug
starting 8 h after infection for a total of 5 days. In vivo efficacy
Drug Discovery Today Volume 25, Number 2  February 2020 REVIEWS
TABLE 7
Models of mucormycosisa
Animal model Method of generation Features of the model Advantages of model Disadvantages of
model
Refs
Mouse OF1 mice immuno-compromised 1 day
before infection with cyclophosphamide
and 5-fluorouracil; challenged
intravenously with Mucor circinelloides
Produces acute invasive
infection, with animals dying
within days after challenge
Allows for survival, tissue
burden, and histopathological
studies in various tissues
Severe model that might
not recapitulate
nondisseminated
infection
[33]
Rabbit New Zealand white rabbits treated with
cytarabine 3 days before challenge;
endotracheal inoculation with
sporangiospores of various species
(Cunninghamella bertholletiae, Rhizopus
oryzae, M. circinelloides or Rhizopus
microsporus)
Development of fungal
pulmonary infarcts
Recapitulates pulmonary
mucormycosis in neutropenic
hosts
Might not recapitulate
nonpulmonary routes of
infection
[54]
Mouse Immunocompromised dBALB/c mice;
subcutaneous injection of R. oryzae
conidial suspension
Cutaneous and soft tissue
infection
Recapitulates features of
cutaneous aspergillosis
Produces nonlethal
phenotype
[56]
Mouse OF1 diabetic mice injected with C.
bertholletiae into lateral tail vein
Produces acute invasive
infection, with animals dying
within days after challenge
Infection studied in a diabetic
setting
Questionable relevance
for nondiabetic settings
[55]
Zebrafish WT AB zebrafish larvae infected with M.
circinelloides; pathogen injected into
hindbrain ventricle (another model using
swim bladder infection also possible)
Filamentous fungal growth
in hindbrain, reaching into
forebrain and invading
ventral muscular tissue
Allows real-time microscopy
analysis of early innate immune
response; mimics range of
aspects of human disease
Limited reproducibility
of disease features in
humans; limited value in
drug efficacy testing
[57]
a Take-home message: COMP would accept data in mice as supportive for potential efficacy. Infection in mice via the intravenous or intrathecal route allows multiple endpoints to be
studied.
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placebo groups of mice. From the experience of COMP, it can be
concluded that such mucormycosis models in immunocompro-
mised animals that recapitulate aspects of the human disease
could be useful in supporting OMPD applications.
Acanthamoeba keratitis
Acanthamoeba are a genus of amphigoric amoebae that is widely
distributed in the environment, being present in the air, soil, and
water. Acanthamoeba spp. cysts are capable of enduring extreme
environmental conditions [58].
Acanthamoeba has two developmental stages: cysts and tropho-
zoites. Although trophozoites are the infective forms, both can
enter the host through the eye, the lower respiratory tract, or
ulcerated or broken skin. When Acanthamoeba spp. adhere to the
eye surface, it can result in keratitis in otherwise healthy individ-
uals, particularly contact lens users. If the parasite invades the host
through the respiratory system or broken skin, it can access the
central nervous system (CNS), causing granulomatous amoebic
encephalitis (GAE), disseminated disease, or skin lesions in indi-
viduals with compromised immune systems.
The main risk factor for acanthamoeba keratitis (AK) is the use
of contact lenses and corneal trauma [59–61]. AK infection can
result in radial neuritis and severe pain [62], eyelid ptosis,
conjunctival hyperemia, and epithelial ulcers [62], often fol-
lowed at later stages by the appearance of a ring-like stromal
infiltrate [62,63]. AK can progress to scleritis and, in severe cases,
ocular enucleation [64]. The pathophysiology of this infection
involves sequential events that includes the production of sev-
eral pathogenic proteases that degrade basement membranes
and induce the cytolysis and apoptosis of the cellular elements
of the cornea, culminating in dissolution of the collagenous
corneal stroma [65].Available models used for AK assessment include in vitro and in
vivo models. In vitro axenic models assess the killing kinetics of
potential treatments against excysted trophozoites. In vivo models
published include mouse, rat, Chinese hamster, rabbit, and pig
models (Table 8). None of the models available fully recapitulates
the disease in humans. Rats and mice developed similar clinical
responses following successful infection after corneal scratching,
scratching followed by corneal cover with contact lens, and intras-
tromal injection. The latter route has shown the highest infection
success rate in rodents [66]. Mice are more infection sensitive, with
higher animal mortality [66]. Although intrastromal injection
results in endophthalmitis, this procedure does not mirror the
natural human infection route. However, the intrastromal injec-
tion model still has innate value for the study of the immunologi-
cal response to Acanthamoeba spp. infection [67].
In contrast to other animal species, Acanthamoeba readily
adheres in vitro to corneas of pigs, Chinese hamsters, and humans
[68,69]. The pig model allowed the evaluation of infections with
Acanthamoeba spp. through application of human contact lenses
[66]. However, unlike the persistent nature of human AK infection,
a spontaneous resolution of the disease usually occurs in pigs. The
Chinese hamster model of infection closely resembles acute-phase
infection in humans [70], but has no nonacute phase and is also
self-limiting [59]. In the rabbit model, infection of the eye led to
necrosis and inflammatory response. The above-described animal
models are considered relevant despite the identified weaknesses;
however, there remains a lack of a comprehensive model that fully
encompasses the pathology of progressive AK in humans. Previ-
ously, COMP has reached positive opinions for initial OMPDs
applications where nonclinical justification was based solely on
observations in vitro. However, it is considered a matter of excep-
tion and normally in vivo data would be needed to support the
assumption of medical plausibility.www.drugdiscoverytoday.com 283
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TABLE 8
Models of AKa
Animal model Methods of generation Features of the model Advantages of model Disadvantages of model Refs
Mouse Intrastromal seeding of
amoebas; scratching of cornea
+ one-time challenge with
pathogen; scratching of cornea
+ continuous challenge with
pathogen through contact lens
application
Acanthamoeba spp.
trophozoites do not bind to
murine cornea; either
debridement in combination
with sufficient pathogen
challenge time or pathogen
injection is necessary for
infection
Availability of mice in large
numbers allowing statistical
analysis; existence of an array of
laboratory reagents
Optimal route of infection
does not represent normal
route of infection in human;
animals might develop
concomitant
endophthalmitis;
spontaneous remission or
lethality can happen
[123]
Rat Intrastromal seeding of
amoebas; scratching of cornea
+ one-time challenge with
pathogen; scratching of cornea
+ continuous challenge with
pathogen through contact lens
application
Acanthamoeba spp.
trophozoites generally do not
bind to rat cornea; either
debridement in combination
with sufficient pathogen
challenge time or pathogen
injection is necessary for
infection
Availability of rats in large
numbers allowing statistical
analysis
Optimal route of infection
does not represent normal
route of infection in human;
animals can develop
concomitant
endophthalmitis;
spontaneous remission can
occur
[123,124]
Hamster: Chinese
hamster, Syrian
hamster
Seeding through contact lenses
after corneal debridement;
intrastromal injection
Acanthamoeba spp.
trophozoites do not adhere to
cornea (see above); corneal
lesions induced by live amoeba
resemble those in infected
human eyes
Ideal model to study
pathogenesis and
immunological response to
Acanthamoeba corneal
infection
Only acute infection occurs;
infected animals show
spontaneous remission,
which does not occur in
humans
[124]
Rabbit Seeding through contact lenses
after corneal debridement;
intrastromal injection;
microinjection anterior to
cornea
Trophozoites rarely bind
naturally to rabbit cornea and,
thus, either debridement before
pathogen challenge or
pathogen injection is generally
necessary for successful
infection to occur
Histopathological similarity to
human disease; high
histological similarity with
human cornea
Infection rates can be as low
as 50%; infection is self-
limiting, unlike in humans;
intrastromal injection can
cause endophthalmitis and
mortality; microinjection, as
opposed to intrastromal
injection, has more
pathophysiological
similarities with infection in
humans, yet does not fully
mimic natural infection
[125,126]
Pig Seeding of pathogen through
contact lenses on intact corneas
Successful infection exhibits
similar pathophysiological
profile to infection in humans,
including lesion signature
Infection can be induced
without corneal debridement;
easier contact lens application
and manipulation; anatomical
and histological similarity of
eye to human
Infection is self-limiting with
spontaneous remission,
unlike in human infections
[67]
a Take-home message: an effective treatment should show sufficient killing kinetics against the trophozoic stage of the amoeba during infection of the ocular surface, such as the cornea.
In that sense, most mammalian ocular environments might represent an acceptable stratum for an in vivo proof-of-concept experiment. However, practical considerations, as well as the
degree of pathophysiological similarity to human infection, make pig, followed by rabbit or hamster, the models most preferred by COMP.
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Leishmaniasis is caused by a heterogeneous group of protozoan
parasites of the genus Leishmania, with visceral leishmaniasis [(VL)
or kala-azar (VL)[most commonly caused by Leishmania donovani
and Leishmania infantum-chagasi [65,66]. The main route of trans-
mission is via the bite of the phlebotomine sand fly. Occasionally,
infection occurs congenitally or through blood transfusion or
organ transplantation. Leishmania invade and replicate within
host macrophages, evading innate and cell-mediated immune
responses. Infection generally appears to persist after clinical cure
of the primary infection [67].
Leishmaniasis comprises a variety of clinical syndromes, in-
cluding skin lesions (cutaneous leishmaniasis, CL), recurring and
irregular fever, loss of appetite, weakness and fatigue, weight loss,
splenomegaly, hepatomegaly and lymphadenopathy, pancytope-
nia (VL), disfiguring lesions on the soft tissues of the mouth, nose
and throat (mucocutaneous leishmaniasis; espundia), and post-
kala azar dermal leishmaniasis (PKDL), which appears 6 months284 www.drugdiscoverytoday.comto 1 or more years after apparent cure of VL. VL is an opportu-
nistic infection in patients with HIV/AIDS or other causes of cell-
mediated immunosuppression and is potentially life threatening
without treatment in both immunocompetent and immunocom-
promised patients.
VL is endemic predominately in developing countries in Latin
America, East Africa, and South-East Asia. In Europe, most cases of
VL occur in Mediterranean countries, and among immunocom-
promised patients.
All OMPDs presented to COMP focused on the treatment of VL
as a chronically debilitating and life-threatening disease variant.
Models for VL are different to those for CL and are summarized in
this section. Generally, in the process of assessment of an OMPD
application, COMP considers that the selection of a model should
be appropriate for the leishmaniasis variant targeted in the devel-
opment of the medicine. For instance, if CL was proposed as an
orphan indication, proof of concept in an appropriate model for
this condition would be needed (Table 9).
Drug Discovery Today Volume 25, Number 2  February 2020 REVIEWS
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naturally occurring animal model of VL (Table 9). However, because
of the heterogeneity of naturally occurring Leishmania strains, dog
breeds, and clinical conditions, this model is expected to be practi-
cally more challenging. In addition, as a big animal, dogs can be
limiting in terms of experimental numbers in cohorts. Thus, rodents
might be more accessible. By contrast, it is more difficult to generate
leishmaniasis in rodents and some observations made in these
models might not be similar or relevant to humans because of the
phylogenetic distance to humans. Hence, the choice of model
should be motivated by the aspect of the condition targeted by
the medicine, accuracy of the endpoints tested, and ethical consid-
erations. The choice of mouse strain, parasite genotype, and stan-
dardized study protocols are important for the successful generation
of in vivo nonclinical data [71]. For example, outbred mouse strains
are generally resistant to L. donovani infections [72].
Malaria
Malaria is a serious relapsing infection in humans, endemic to
tropical and subtropical regions of the world. It is caused by five
recognized species of the related protozoan parasites of the genus
Plasmodium that are known to affect humans, Plasmodium malariae,
Plasmodium vivax, Plasmodium ovale, Plasmodium falciparum, and,
less commonly, Plasmodium knowlesi [73,74]. The parasite is trans-
mitted to humans by the mosquito vector when it feeds on human
blood. The immature form of the parasite, sporozoites, enter the
human bloodstream, passing through the bite wound and, once
inside the host, the parasite rapidly multiplies by asexual reproduc-
tion in the liver. During this latent period, the asexual forms, called
merozoites, are formed and emerge from the liver into the peripheral
blood, causing the symptomatic disease course. Typically, symp-
toms occur 10–28 days after infection. The first clinical signs can be
any combination of chills, fever, headache, muscle ache, nausea,
vomiting, diarrhea, and abdominal cramps. Chills and fever occur in
periodic attacks. Severe malaria is more acute, with signs of organ
dysfunction and/or high level of parasitemia [74].
All OMPD applications received by COMP aimed to treat severe
malaria, where treatment options remain limited and the disease is
life threatening. Nonclinical models presented in OMPD applica-
tions included rodent and NHP models of severe malaria, most of
which are generated with nonspecific-to-human strains of Plasmo-
dium (Table 10). Such models were accepted by COMP as support-
ive of the medical plausibility of the product in treatment of severe
malaria. However, data from such models would be considered
insufficient to support significant benefit over authorized antima-
larial medicines because of difference in the parasites causing
human disease. Therefore, all successful applications to data have
included also clinical data, which allowed the assessment of the
relative efficacy of the proposed medicine in the context of the
current standard of care.
The existing models of malaria most often recapitulate many
but not all features of human disease. However, they can be used
with success for screening candidate drugs, especially if transgenic
Plasmodium parasites are utilized. This could be useful for, for
example, when the medicine is a vaccine or targets the mechanism
of P. falciparum sequestration (the adherence of infected erythro-
cytes to the endothelium of blood vessels [75]) (Table 10). It is
difficult to reproduce human cerebral malaria in rodent modelsand, thus, the only rodent model described to recapitulate cerebral
malaria, P. berghei ANKA in mice, should be explored if the activity
of the medicine is meant to target this clinical presentation [76].
Importantly, in rodent models, malaria can clear itself and one has
to study the drug effect before the expected natural clearance and
with inclusion of an appropriate vehicle control. Therefore, the
high-quality reporting of the study protocols would be considered
important for COMP assessment. Also, the choice of clinically
relevant endpoints should match the symptoms developed by the
given model and the endpoints should be of functional relevance
to disease in humans (Table 10).
Discussion
Rare infectious diseases might affect limited numbers of European
citizens, but they represent a major public health issue for several
reasons: (i) some are endemic in certain European regions; (e.g.,
leishmaniasis and drug-resistant TB); (ii) some have the potential
to cause largeand lethalepidemics (e.g.,EVD infection); (iii) some are
agents of bioterrorism (e.g., anthrax or smallpox); and (d) some are
neglected diseases affecting mainly the developing world, while
rarely seen among returning European travelers (e.g., malaria). More-
over,climatechangeandimprovedtraveloptionsoflimitedduration
both for human and animal carriers are expected to have an impact
on the incidence, prevalence, and distribution of infections acquired
through various routes (arthropod vector, rodent, water, food, and
air), and many infectious diseases that are currently considered as
rare in Europe may re-emerge as impending threats [77].
Neglected tropical diseases affect more than 1 billion people,
primarily low-income populations (poor, living in remote, rural
areas, urban slums, or conflict zones) and these diseases have a
low status in public health priorities in the developing world. There
is interest in driving pharmaceutical development to the area of
Neglected Tropical Diseases (NTDs) in the European regulatory
system, and the EMA, in cooperation with the WHO, has a mecha-
nism to provide scientific opinions on human medicines, including
vaccines, that are intended exclusively for markets outside of the EU,
under what is usually designated an ‘Article 58’ procedure [78]. In
addition, in this therapeutic area where few incentives exist, the
European Orphan Drug regulation could offer research and devel-
opment incentive for sponsors seeking the development of medi-
cines for neglected communicable diseases (e.g., Ebola or Zika virus).
Orphan-designated medicines profit from enhanced development
support via the EMA protocol assistance scheme, reductions in
regulatory fees, along with other incentives. Examples for such
support through the European orphan framework are orphan drugs
for the development of medicines for the treatment of Ebola infec-
tion and of other life-threatening diseases, such as malaria.
Regulatory support for the development of medicines in rare
infectious diseases can be considered useful when recognizing that
the development of new drugs and vaccines is challenging and
human data on pathophysiology, clinical spectrum, laboratory
findings, and therapy are scarce, often derived from case reports
and small case series. In addition, for many pathogens, the resultant
disease is potentially lethal or permanently disabling for humans
and, therefore, research using humans is not feasible. Thus, the
development of safe and efficacious vaccines and antimicrobials
must rely on the use of appropriate animal models available to
researchers. The application of Koch’s postulates early in the historywww.drugdiscoverytoday.com 285
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TABLE 9
Models of VLa
Animal model Method of generation Features of the model Advantages of model Disadvantages of
model
Refs
Mouse: BALB/c,
C57BL/6
Intradermal or intravenous
infection with Leishmania
donovani, Leishmania.
major or Leishmania
infantum amastigotes
Disseminated granulomas with
parasitized macrophages;
infection slowly resolves after 4–
8 weeks in cure types; low dose
infection induces less immune
protection, intradermal
infection yields higher parasite
load
Useful to study immunology,
vaccines, chemotherapy,
examines activity of drug
against liver infection
Does not exhibit the
spleen infection, can
self-cure in some
strains
[127–130]
Mouse
immunodeficient
SCID or nu/nu
Intravenous infection with
L. donovani amastigotes
No induction of macrophage
activation, because of lack of
immune response, atypical
granulomas form later
Useful to study leishmaniasis
in immunosuppressed cases
Limited applicability
in context of clinical
immunocompetence
[131,132]
Hamster: Chinese
hamster, Syrian
golden hamster
Intradermal or intracardial
infection with L. donovani
amastigotes
Inability of infected antigen-
presenting cells to stimulate
specific T cells, macrophage
impairment, progressive disease
leading to death
Useful to study pathology
and chemotherapy; more
synchronous infection in
liver and spleen that can
develop into a chronic
noncure infection more
similar to human VL
Lack of available
reagents
[133–135]
Rat: African white-
tailed rat
Intraperitoneal infection
with L. donovani or
Leishmania braziliensis
Long-term disease, good for
maintenance of parasites
Excellent host for in vivo
maintenance and long-term
experiments with L.
donovani and L. braziliensis
Not specifically noted
in consulted
literature
Rat: Cotton rat
(Sigmodon hispidus)
Persistent infection, progressive
lethal disease
Some of the most
susceptible animal hosts for
L. donovani
[136,137]
Rat: M. natalensis, a
multi-mammate rat
[138]
Dog: different breeds Natural infection with
Leishmania chagasi or
experimental intradermal
or intravenous inoculation
of L. donovani amastigotes
Some infected dogs remain
asymptomatic.
Lymphoadenopathy, weight
loss, anemia,
hypergammaglobulinemia, and
dermatitis leading to death
Useful to study pathology,
vaccines, chemotherapy;
dog is not a reservoir of L.
donovani; reproduces
natural infection similar to
human disease
Limited for ethical
reasons; availability
of naturally infected
dogs might be
limited
[130,139–141]
NHPs: Langurs, vervet
monkey, rhesus
monkey, mandrills,
owl monkey, baboon,
marmoset, squirrel,
Sykes monkey
Intravenous inoculation of
L. donovani amastigotes
Owl and squirrel monkey
develop acute, fulminant but
short-lived infection; Rhesus
monkeys develop low burden or
inconsistent infections; Langurs
develops a progressive acute
and fatal disease, similar to
human kala-azar
Useful to study pathology;
Indian langur presents all
clinical immuno-
pathological features of
human kala-azar. Normally
used to study vaccines
Limited use for
ethical reasons
[73,142–144]
a Take-home message: taken together, COMP would find mouse models of leishmaniasis acceptable because of pathophysiological similarity as well as accessibility. Dog models would be
viewed as more accurate representations of human disease, but would not be required on ethical grounds.
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study of infectious diseases. Nowadays, and after the implementa-
tion of the marketing authorization under exceptional circum-
stances in the EU [79] and the ‘Animal Rule’ by the FDA [80],
animal models are used to provide nonclinical safety and efficacy
data for the evaluation of most new antimicrobial agents. This is
considered acceptable provided that the applicant describes the
relevant principles of medical ethics with precise reference to inter-
nationally accepted guidelines on ethics [81].
Medical plausibility at the time of initial orphan designation
According to the European Orphan Regulation, the applicant can
apply for an OMPD at any stage of product development as long as the
‘intent to treat/prevent or diagnose’ can be demonstrated. This intent
to treat, otherwise phrased as ‘medical plausibility’, requires a certain
level of evidence, which allows for making an assumption of a disease-286 www.drugdiscoverytoday.comrelevant activity of the medicine in the condition, as applied for [81].
Inthecontextof infectiousdiseases, it isexpectedthatnonclinicaldata
need to be generated in appropriate models of the condition (Fig. 1).
In vitro data on the efficacy of a new anti-infective agent might
be an alternative to animal models, because they are already
usually the first building block for proving activity of a potential
new anti-infective. COMP is aware of the development of complex
systems for in vitro testing of, for example, pathogen clearance/
load or mathematical and computer modeling systems. For the
acceptability of such new methods, validation with regard to the
clinical translatability and clinical relevance is crucial. Generally,
in vitro data can be used along with animal in vivo data for better
establishing the efficacy of a new agent, but, currently, in vitro data
alone would be only exceptionally accepted by COMP (Fig. 1). This
could be the case if no relevant in vivo model can be generated and
there were no medicinal products addressing the disease, or if in
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TABLE 10
Models of malariaa
Animal model Method of generation Features of the Model Advantages of model Disadvantages of model Refs
Rat Intravenous inoculum
[Plasmodium berghei (Pb)-
parasitized erythrocytes]
using parasite strain
passaged three times
through rats
Parasitemia peaking on day
11, 21 days of disease length,
high degree of self-
clearance, 17% mortality
High infection rate, good for
study of infection kinetics
and parasitemia inhibition
High rate of self-clearance of
parasitemia; surrogate
models needed because Pb
does not infect humans
[145]
Mouse Intradermal or intravenous
inoculum of parasitized
erythrocytes [PB ANKA (PbA);
but Plasmodium yoelii,
Plasmodium chabaudi,
Plasmodium vinckei also
infect mice]
Severe disease caused by
PbA, with neurological
symptoms or coma, strong
immune reaction, acute lung
and liver pathology,
metabolic acidosis, fatal
outcome
Relevant models for
studying mechanism of
immune response,
antimalarial of general
mechanism of action not
specific to human malaria;
PbA model relevant to study
cerebral malaria
High rate of self-clearance of
parasitemia; surrogate
models needed because PbA
and others do not infect
humans
[77,129]
Rodent Parasites that express
Plasmodium falciparum
VAR2CSA or CSA binding
domains on the surface of
infected red blood cells
(iRBCs); transgenic P. berghei
parasites in rodents
Antibodies developed in
mice or rats, but screening of
antibody affinity done only
ex vivo so far
Such parasites in
combination with a
‘humanised placental
malaria mouse model’ might
offer screening system for in
vivo testing of inhibitors that
block P. falciparum
sequestration
Surrogate models in absence
of in vivo activity screening
[146,147]
Mouse: NOD/
SCID or FRG
(humanized)
Engrafted with human
erythrocytes or hepatocytes;
intraperitoneal inoculation
of P. falciparum 3D7-infected
red blood cells
Depending on model, only
some stages of Plasmodium
life cycle can be reproduced;
parasites accumulate in
several organs
Good for research of
medicines in
immunocompromised
setting; research of
antimalarials targeting
erythrocytic stages
Parasitemia not maintained;
whole life cycle of parasite
not easily reproduced
[148–152]
Gerbil Infected by PbA via
intraperitoneal injection of
infected red blood cells
Weight loss, hypothermia,
anemia, splenomegaly,
hepatomegaly
Similarity with human
condition (splenomegaly,
hepatomegaly);
pathogenesis of severe
malaria can be studied
No involvement of nervous
system; limited use because
of paucity of reagents
specific to gerbil
[153]
NHPs: M. mulatta,
olive baboon,
Rhesus monkey,
Saimiri and Aotus
monkeys
P. knowlesi, Plasmodium
cynomolgi, Plasmodium
vivax, Plasmodium ovale etc.-
parasitized erythrocytes
Severe disease, almost
always lethal; mimics P.
falciparum infected red
blood cell sequestration and
resetting; cerebral infected
red blood cell sequestration
and neurological signs; full
life-cycle of parasite
reproduced
Good model of human
cerebral malaria; large
overlap between antibody
isotypes of Aotus and human
makes this model applicable
for vaccine screening and
could complement research
in other models
Limited use for ethical
reasons; limited availability
of reagents specific to NHPs
[154,155]
a Take-home message: appropriate mouse models exist that can be used to demonstrate medical plausibility in malaria. Careful study design would be required to avoid the pitfalls
associated with known limitations of these models.
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and support clinical translatability (Fig. 1).
Of 60 applications reviewed for this analysis, 24 contained non-
clinical data only, indicating that 40% of applications for rare
infectious diseases were for products that had not yet been evaluated
in humans. Significant benefit was not required in 38% of the
designated conditions. Interestingly, these were mainly viral dis-
eases, suggesting a higher unmet need in these conditions. This
review of previous COMP assessments showed that the selection of
an appropriate animal model is vital. If there is no possibility to
generate clinical data, the need for animal models of higher order
(dogs or NHPs) might be exceptionally required, and this is assessed
on a case-by-case basis. For example, it might be impossible to test
Ebola vaccines and treatments in NHPs or in patients. The selection
of the appropriate pathogen (genus, species, and strain) is as crucial
as the selection of the animal model. As an example, the Reston
strain of Ebola virus that causes disease and death in primates doesnot cause disease in humans [82] and, therefore, cannot be accepted
in an animal model. In general, laboratory-adapted strains of patho-
gens tend to become attenuated through successive cultures in
artificial media, whereas clinical strains better mimic the human
condition. The use of human unspecific disease strains (e.g., rodent
specific strains of Plasmodium) must be justified and contextualized
with regardsto, for example, the common mechanism of the activity
of the medicine. The use of a model of a different disease would be
only accepted if the generation of an appropriate model was techni-
cally challenging and ethically questionable (e.g., as in the case of
smallpox infection).
Disease-relevant endpoints
This review of previous COMP assessments also demonstrates that
the time points for therapeutic intervention and the efficacy
assessment in animal models should accurately reflect the human
disease presentation. In many cases, the animal models might notwww.drugdiscoverytoday.com 287
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Is there a nonclinical model presenting
with features of the condition targeted
by the product?Yes No
NoNo
No No
Yes Yes
Yes
YesYesYesYes
Yes
Can functional endpoints
be measured using this
model?
Can a surrogate endpoint
be measured, which
would be predictive of a
disease-relevant activity?
Is this model used and
are functional endpoints
measured for proof of
concept? Are the effects
significant?
There is medical
plausibility
There is medical
plausibility
The medical plausibility
can be assessed with
caution
The medical plausibility
can be assessed with
caution
Is this model used and
surrogate endpoints
mesured? Are data/
literature submitted to
justify the causative link 
to functional
improvement?
Are any early clinical data
available? Are the effects
significant?
Is the mode of action
understood/proposed?
Can a model of a similar
condition be used to
demonstrate the same
mode of action, which
would translate into a
disease-relevant activity
If available, assess a
combination of in vitro
data
and in vivo data in a
surrogate model
Availability of models
Relevance of
endpoints
Achievable level
of nonclinical
evidence
Relative difficulty
of assessment
Drug Discovery Today 
FIGURE 1
Schematic illustrating the process of assessment of medical plausibility by the Committee for Orphan Medicinal Products (COMP). Reproduced from [10].
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clinical signs might not be the same as in humans. COMP strongly
encourages the use of efficacy endpoints that can be linked to the
human pathology and symptoms. Often, infectious disease re-
search studies cause considerable animal pain or distress. As an
example, some studies require infected animals to exhibit signifi-
cant clinical disease, similar to that observed in infected humans,
before administration of an antimicrobial agent, or in the case of
controls, no antimicrobials are administered. Therefore, endpoints
should be clearly defined to allow the earliest removal of an animal
from an experiment, with the goals of preventing unnecessary
animal suffering while achieving the desired scientific results.
Animal death should be used as an endpoint only exceptionally,
because earlier endpoints should be preferred when applicable.
Nevertheless, in several types of infection, it was the survival that
was perceived as the most informative functional outcome in
existing nonclinical models (Table 1).
Standardization of nonclinical tests
The assessment of nonclinical studies in OMPD applications was
sometimes challenging because of the limited information sub-
mitted about the nonclinical models used or on the methods used
in the experiments. Therefore it is vital that studies are conducted
in accordance with state-of-the-art scientific standards and that all
relevant information is reported in the submission document, as288 www.drugdiscoverytoday.comexemplified by documents such as the ARRIVE guideline [83].
Details such as animal genetics, the species and strain of pathogen,
the experimental procedures, supportive care, medications, and
the relevance of endpoints to human should be described fully, to
allow COMP to assess the application with the scientific rigor
applicable to the early stage of development. The application of
standardized study protocols and studies designed to be informa-
tive for the intended clinical use of the medicine [83] would be in
line with the spirit of the ‘replace, reduce, refine (3Rs) of animal
research’ efforts [9,84].
Concluding remarks
COMP required either animal model studies or clinical data for
most of the 60 applications for rare infections included in this
analysis. Based on COMP experience, the selection of the ap-
propriate animal model for each infection should be guided by
multiple factors, such as the characteristics of the animal species
and the infecting organism, the similarity of the experimental
infection with human infection in terms of disease course
and symptoms, and the endpoints that can be used in the
animal experiments and their translational value for the
human situation (for a graphic summary see also Fig. 1 in
[10]). In view of the need to eventually replace animal experi-
ments, COMP would support the development of in vitro mod-
els, their standardization, and validation. Applicants should
Drug Discovery Today Volume 25, Number 2  February 2020 REVIEWSalways be aware of the potential limitations of their models and
extrapolate cautiously their findings to the human condition. In
the experience of COMP, it is vital that the applicants adhere to
the animal welfare guidelines and comply with applicable reg-
ulations, and are encouraged to fully report all experiment
details [83].V
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GLOSSARY
Disease-relevant endpoint measurement in a nonclinical
study that can be translated into therapeutic activity. This is
most often a functional endpoint, but can sometimes be a
well-established intermediate measure (e.g., neuronal
connectivity, conduction velocity, etc.).
Disease-relevant activity here understood as the
pharmacodynamic (PD) activity of the product, which
translates into improvement in functional and disease-
specific endpoints. This term is used in the context of
nonclinical data and is conceptually equal to the term
‘efficacy’, which is reserved for clinical development.
Medical plausibility a demonstration of the intent to treat
the proposed condition using the proposed medicinal
product. For the demonstration of medical plausibility, the
sponsor has to provide data in patients or in a model of the
condition (usually in vivo) that show a disease-relevant PD
activity of the medicinal product.
Orphan medicinal product designation (OMPD) a status
awarded to a medicinal product in development once
eligibility criteria laid down in the orphan legislation are met.
In Europe, the eligibility is assessed by COMP and the positive
opinion is then considered by the EC for the entry into the
European orphan medicinal products register.
Significant benefit a requirement specific to the European
orphan legislation, required when other medicines are
authorized for the treatment of the same condition.
Significant benefit can be understood as a clinically relevant
advantage (e.g., improved efficacy) or a major contribution
to patient care (e.g., an improvement affecting quality of life).
Surrogate disease model a model of a disease, with only a
limited representation of disease features (e.g., similar
pathophysiology and only one of the disease features).
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